In September 2015, NICE published the Final Appraisal Determination (FAD) for adalimumab, etanercept, infliximab and golimumab for treating ankylosing spondylitis and non radiographic axial spondyloarthritis. However, publication of the final guidance has been delayed due to an appeal from the pharmaceutical company MSD. At the last moment MSD withdrew their appeal so we are now just waiting for the Technology Appraisal Guidance (TAG) to be published.
Read more about this progress from the NASS website.
NICE set to appraise secukinumab for AS
In 2016, NICE will be conducting a Single Technology Appraisal (STA) of secukinumab for treating ankylosing spondylitis after inadequate response to non-steroidal anti-inflammatory drugs or anti TNFs. NASS will be putting in a submission by the end of January. Any submissions we make to NICE are guided by the views of people living with the condition. Therefore we will be carrying out a short survey among people living with AS in January 2016. At the moment NICE hope to publish guidance on secukinumab in October 2016.
Fab at 40 Fortnight
In 2016 NASS is celebrating our 40th birthday. The 1st to 15th May 2016 will be Fab at 40 Fortnight.
More information to come in the New Year.